Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights
matched for mean body weight at the start of treatment at 770 g 10 g) received daily IP injections of vehicle (1 mL/kg), sCT (3 g/kg), liraglutide (50 g/kg), a combination of sCT and liraglutide (3 g/kg + 50 g/kg) or a stepwise administration of the amylin and GLP-1R analogs, where rats received sCT treatment for the first week, liraglutide treatment for the second week, followed by a combination treatment of sCT and liraglutide for the remaining testing period
Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial
THE CLAIM: Drinking diet soda increases risk for Type 2 diabetes, high blood pressure, and heart disease
Clean both the vial stopper and injection site with alcohol swabs
Other conditions showing signals Emerging research suggests potential benefit in gout (reduced risk of development in GLP-1 users), osteoarthritis (improved joint outcomes in semaglutide users), and endometriosis (anti-inflammatory mechanisms relevant to endometrial inflammation)